SCHEMBL8343286

SCHEMBL8343286

Nc1nc(OCc2ccccc2)c2nc(N)[nH]c2n1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MPO P05164 9/20 0.59
MGMT P16455 4/20 0.59
CYP3A4 P08684 2/20 0.59
TPO P07202 1/20 0.59
EPX P11678 1/20 0.59
CDK1 P06493 2/20 0.52
CCNB1 P14635 2/20 0.52
CCNA2 P20248 2/20 0.52
CDK2 P24941 2/20 0.52
CCNA1 P78396 2/20 0.52
LMNA P02545 1/20 0.52
CYP1A2 P05177 1/20 0.52
CYP2D6 P10635 1/20 0.52
CYP2C9 P11712 1/20 0.52
TSHR P16473 1/20 0.52
NFKB1 P19838 1/20 0.52
CYP2C19 P33261 1/20 0.52
BLM P54132 1/20 0.52
PMP22 Q01453 1/20 0.52
PIN1 Q13526 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8723557 0.81 MPO (0.54) MPOMGMTCYP3A4TPOEPX
SCHEMBL8006001 0.81 MPO (0.51) MPOMGMTCYP3A4TPOEPX
6-O-Benzylguanine SCHEMBL29405347 0.80 MGMT (0.63) MPOMGMTCYP3A4TPOEPX
6-O-Benzylguanine SCHEMBL600698 0.80 MGMT (0.63) MPOMGMTCYP3A4TPOEPX
6-O-Benzylguanine SCHEMBL4631743 0.79 MGMT (0.61) MPOMGMTCYP3A4TPOEPX
SCHEMBL19295446 0.79 MPO (0.58) MPOMGMTCYP3A4TPOEPX
SCHEMBL21878057 0.78 MPO (0.48) MPOMGMTCYP3A4TPOEPX
SCHEMBL3300895 0.77 PIN1 (0.67) MPOMGMTCYP3A4TPOEPX
SCHEMBL16852229 0.76 MGMT (0.64) MPOMGMTCYP3A4TPOEPX
SCHEMBL3300630 0.75 MGMT (0.56) MPOMGMTCYP3A4TPOEPX

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120252791-A1 Heterocyclic GTP Cyclohydrolase 1 Inhibitors For the Treatment of Pain CHILDREN'S MEDICAL CENTER CORPORATION 2012-10-04 US disclosed
US-5912252-A Purine and guanine derivatives as PNP inhibitors DARWIN DISCOVERY LIMITED (GB) 1999-06-15 US disclosed
EP-0873339-A1 PURINE AND GUANINE DERIVATIVES AS PNP INHIBITORS Chiroscience Limited (GB) 1998-10-28 EP disclosed
US-5736549-A INHIBITORS OF PURINE NUCLEOSIDE PHOSPHORYLASE, USED FOR TREATING OR PREVENTING TISSUE REJECTION OR SELECTIVE SUPPRESSION OF MAMMALIAN T-CELL FUNCTION CHIROSCIENCE LIMITED (GB) 1998-04-07 US disclosed
EP-0784624-A1 PURINE AND GUANINE COMPOUNDS AS INHIBITORS OF PNP Chiroscience Limited (GB) 1997-07-23 EP disclosed
WO-1997012887-A1 PURINE AND GUANINE DERIVATIVES AS PNP INHIBITORS CHIROSCIENCE LIMITED (GB) 1997-04-10 WO disclosed
WO-1996011200-A1 PURINE AND GUANINE COMPOUNDS AS INHIBITORS OF PNP CHIROSCIENCE LIMITED (GB) 1996-04-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120252791-A1 Heterocyclic GTP Cyclohydrolase 1 Inhibitors For the Treatment of Pain GGH, GGPS1, GGT1 MPO 329/4885MGMT 1636/4885CYP3A4 1973/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.